Corcept Therapeutics Officer Executes $2.91M Pre-Planned Option Exercise & Sale

Transaction Overview

On October 5, 2026, Sean Maduck, President of Corcept Endocrinology at Corcept Therapeutics Inc ($CORT), reported the exercise and liquidation of stock options covering 25,000 shares of common stock executed across October 1 and October 2, 2026.

• Option Exercises (Code M):

  • October 1, 2026: 413 shares exercised at an exercise price of $8.27.
  • October 2, 2026: 24,587 shares exercised at an exercise price of $8.27.
  • Total Exercise Cost: $206,750.00.

• Open Market Sales (Code S):

  • October 1, 2026: 413 shares sold at a weighted average price of $115.5373.
  • October 2, 2026: 15,843 shares sold at a weighted average price of $116.1233.
  • October 2, 2026: 8,744 shares sold at a weighted average price of $116.5534.
  • Total Gross Sale Proceeds: $2,906,601.27.

10b5-1 Plan and Significance

The sales were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025. Because this was a simultaneous option exercise and sale where the options were set to expire in February 2027, the reporting person's direct common stock balance remained neutral at 9,938 shares (which includes 1,424 unvested restricted stock awards).

In addition to direct holdings, Maduck maintains indirect ownership of 109,717 shares through trusts and family investment entities (Living Trust, GRATs, and LLCs). Given the non-discretionary 10b5-1 execution and zero reduction in net base direct equity, the market signal is considered Low.